Drugs Made In America Acquisition Corp
NASDAQ:DMAA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sentry Technology Corp
OTC:SKVY
|
US |
|
Ito Yogyo Co Ltd
TSE:5287
|
JP |
|
A
|
Alamo Energy Corp
OTC:ALME
|
US |
|
O
|
Oxiquim S A
SGO:OXIQUIM
|
CL |
|
Q
|
Qingdao Victall Railway Co Ltd
SSE:605001
|
CN |
|
B
|
Barclays PLC
OTC:BCLYF
|
UK |
|
TIE Kinetix NV
AEX:TIE
|
NL |
|
S
|
SLB Development Ltd
SGX:1J0
|
SG |
|
A
|
Abbott Laboratories
XBER:ABL
|
US |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
D
|
Drugs Made In America Acquisition Corp
NASDAQ:DMAA
|
352.3m USD |
Loading...
|
|
| US |
|
SoFi Technologies Inc
NASDAQ:SOFI
|
20.1B USD |
Loading...
|
|
| MC |
|
HAL Trust
AEX:HAL
|
15.4B EUR |
Loading...
|
|
| US |
|
WP Carey Inc
NYSE:WPC
|
15.4B USD |
Loading...
|
|
| US |
|
Annaly Capital Management Inc
NYSE:NLY
|
14.9B USD |
Loading...
|
|
| US |
|
Ares Capital Corp
NASDAQ:ARCC
|
12.7B USD |
Loading...
|
|
| KY |
C
|
Compass Digital Acquisition Corp
NASDAQ:CDAQ
|
9.4B USD |
Loading...
|
|
| BE |
|
Sofina SA
XBRU:SOF
|
7.6B EUR |
Loading...
|
|
| US |
|
AltC Acquisition Corp
NYSE:OKLO
|
7.7B USD |
Loading...
|
|
| US |
|
Starwood Property Trust Inc
NYSE:STWD
|
6.3B USD |
Loading...
|
|
| KY |
J
|
JATT Acquisition Corp
F:1GU
|
4.6B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Drugs Made In America Acquisition Corp
Glance View
Drugs Made In America Acquisition Corp. is a blank check company. The company is headquartered in Fort Lauderdale, Florida. The company went IPO on 2025-01-28. The firm is incorporated as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. Its efforts to identify a prospective target business will not be limited to a particular industry or geographic region although it intends to focus its search for business combination targets in the pharmaceutical industry.
